Literature DB >> 10499778

Antioxidant status and lipid peroxidation in hemodialysis patients undergoing erythropoietin and erythropoietin-vitamin E combined therapy.

M Inal1, G Kanbak, S Sen, F Akyüz, E Sunal.   

Abstract

In this study, plasma and red blood cell (RBC) antioxidant status and plasma lipid peroxidation were investigated in 46 hemodialysis patients. In addition, the effect of erythropoietin (EPO) and EPO-vitamin E combination therapy on plasma and RBC antioxidant status, and plasma lipid peroxidation were examined. There were 10 healthy subjects in the control group and 10 hemodialysis patients in the untreated group. The third group included 36 hemodialysis patients that were given EPO (100 U/kg) for 3 months, 3 times per week. The fourth group included 36 hemodialysis-patients from the EPO group that were given EPO at a 50% decreased dose + vitamin E (300 mg/day) for 3 months. MDA levels in the untreated group, the EPO group and the EPO + vitamin E groups were found to be higher than the control group (p < 0.001, in both). Furthermore, MDA levels in both of the treatment groups were lower when compared to the untreated group (p < 0.001, in both). Plasma vitamin E levels in the untreated, the EPO group and EPO + vitamin E groups were lower than the control group (p < 0. 001). In contrast, plasma vitamin E levels in the treatment groups were higher in comparison with the control group (p < 0.05). SOD activities in the untreated, the EPO group and the EPO + vitamin E groups were found to be lower than the control group (p < 0.001). SOD activities in the treatment groups were higher than the control group (p<0.001). The SOD activities in the EPO+vitamin E group increased when compared to the EPO group (p < 0.001). CAT activities in the untreated, the EPO group and the EPO + vitamin E groups were found to be lower than the control group (p < 0.001 in untreated and EPO groups, p <0.01 in EPO+ vitamin E group). CAT activities in EPO and EPO+ vitamin E groups were increased when compared to the untreated group (p < 0.01). In conclusion, our findings have shown that antioxidant status decreased and lipid peroxidation increased in hemodialysis patients. EPO has an antioxidant effect on the RBC and plasma antioxidant status, and plasma lipid peroxidation. These effects were moderately increased by the combination of vitamin E and EPO.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499778     DOI: 10.1080/10715769900300771

Source DB:  PubMed          Journal:  Free Radic Res        ISSN: 1029-2470


  9 in total

1.  Oil pollution increases plasma antioxidants but reduces coloration in a seabird.

Authors:  Cristóbal Pérez; Marta Lores; Alberto Velando
Journal:  Oecologia       Date:  2010-06-09       Impact factor: 3.225

2.  Malondialdehyde can predict survival in hemodialysis patients.

Authors:  Crina Claudia Rusu; Simona Racasan; Ina Maria Kacso; Diana Moldovan; Alina Potra; Ioan Mihai Patiu; Dan Vladutiu; Mirela Gherman Caprioara
Journal:  Clujul Med       Date:  2016-04-15

Review 3.  Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.

Authors:  Nans Florens; Catherine Calzada; Egor Lyasko; Laurent Juillard; Christophe O Soulage
Journal:  Toxins (Basel)       Date:  2016-12-16       Impact factor: 4.546

Review 4.  Oxidative Stress in Hemodialysis Patients: A Review of the Literature.

Authors:  Vassilios Liakopoulos; Stefanos Roumeliotis; Xenia Gorny; Evangelia Dounousi; Peter R Mertens
Journal:  Oxid Med Cell Longev       Date:  2017-09-12       Impact factor: 6.543

5.  The effects of vitamin E supplementation on malondialdehyde as a biomarker of oxidative stress in haemodialysis patients: a systematic review and meta-analysis.

Authors:  Peter Bergin; Aoife Leggett; Chris R Cardwell; Jayne V Woodside; Ammarin Thakkinstian; Alexander P Maxwell; Gareth J McKay
Journal:  BMC Nephrol       Date:  2021-04-09       Impact factor: 2.388

6.  Erythropoietin therapy improves endothelial function in patients with non-dialysis chronic kidney disease and anemia (EARNEST-CKD): A clinical study.

Authors:  Jina Lim; Chung Jo Yu; Hoon Yu; Sang Jin Ha
Journal:  Medicine (Baltimore)       Date:  2021-10-22       Impact factor: 1.817

7.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

8.  How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients.

Authors:  Zorica M Dimitrijevic; Tatjana P Cvetkovic; Vidojko M Djordjevic; Dusica D Pavlovic; Nikola Z Stefanovic; Ivana R Stojanovic; Goran J Paunovic; Radmila M Velickovic-Radovanovic
Journal:  Int J Med Sci       Date:  2012-10-26       Impact factor: 3.738

9.  Diminution of Oxidative Damage to Human Erythrocytes and Lymphocytes by Creatine: Possible Role of Creatine in Blood.

Authors:  Neha Qasim; Riaz Mahmood
Journal:  PLoS One       Date:  2015-11-10       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.